METHODS FOR TREATING HAIR LOSS AND COMPOSITIONS FOR SAME
Compositions and methods for treating hair loss in a patient by intradermal injection using liquid composition containing minoxidil and a secondary active agent in a pharmaceutically acceptable excipient are described herein.
1 . A composition for treating hair loss in a subject comprising minoxidil and a secondary active agent in a pharmaceutically acceptable carrier.
2 . The composition of claim 1 , wherein the minoxidil has a concentration of about 0.25% (w/w) to about 15% (w/w).
3 . The composition of claim 1 , wherein the secondary active agent is selected from the group consisting of finasteride, dutasteride, tofacitinib, tacrolimus, bimatoprost, latanoprost, spironolactone, aldactone, kenalog-10, kenalog-40, triamcinolone, azulfidine, sulfasalazine, and sulfazine.
4 . The composition of claim 2 , wherein the secondary active agent comprises about 0.001% (w/w) to about 5% (w/w) of the total composition.
5 . The composition of claim 1 , wherein pharmaceutically acceptable carrier is phosphate buffered saline solution, water, or saline.
6 . The composition of claim 4 , wherein the minoxidil, secondary active agent, and phosphate buffered saline solution, water, or saline are the only components of the formulation.
7 . The composition of claim 1 , further comprising a penetration enhancer.
8 . The composition of claim 6 , wherein the penetration enhancer is selected from the group consisting of carriers and vehicles, chemical penetration enhancers, diols, polyols, fatty acids, fatty alcohols, fatty acid esters, surfactants, pyrrolidones, and combinations thereof.
9 . The composition of claim 6 , wherein the penetration enhancer comprises about 1% (w/w) to about 20% (w/w) of the total composition.
10 . The composition of claim 1 , further comprising an antioxidant selected from the group consisting of butylated hydroxytoluene, ascorbic acid, ascorbic palmitate, butylated hydroxyani sole, 2,4,5-trihydroxybutyrophenone, 4-hydroxymethyl-2,6-di-tert-butylphenol, erythorbic acid, gum guaiac, propyl gallate, thiodipropionic acid, dilauryl thiodipropionate, tert-butylhydroquinone, tocopherol, and pharmaceutically acceptable salt and ester thereof, and combinations thereof.
11 . A method for treating hair loss comprising:
administering a therapeutically effective amount of a composition comprising minoxidil and a secondary active agent in a pharmaceutically acceptable carrier to a subject in need of treatment.
12 . The method of claim 10 , wherein administering comprises intradermal injection.
13 . The method of claim 10 , wherein administering comprises injecting the composition into dermis of the scalp.
14 . The method of claim 10 , wherein the secondary active agent is selected from the group consisting of finasteride, dutasteride, tofacitinib, tacrolimus, bimatoprost, latanoprost, spironolactone, aldactone, kenalog-10, kenalog-40, triamcinolone, azulfidine, sulfasalazine, and sulfazine.
15 . The method of claim 10 , wherein the secondary active agent comprises about 0.001% (w/w) to about 5% (w/w) of the total composition.
16 . The method of claim 10 , wherein pharmaceutically acceptable carrier is phosphate buffered saline solution, water, or saline.
17 . The method of claim 15 , wherein the minoxidil, secondary active agent, and phosphate buffered saline solution, water, or saline are the only components of the formulation.
18 . The method of claim 10 , further comprising a penetration enhancer.
19 . The method of claim 11 , wherein the penetration enhancer comprises about 1% (w/w) to about 20% (w/w) of the total composition.
20 . The method of claim 11 , wherein the composition further comprises an antioxidant selected from the group consisting of butylated hydroxytoluene, ascorbic acid, ascorbic palmitate, butylated hydroxyanisole, 2,4,5-trihydroxybutyrophenone, 4-hydroxymethyl-2,6-di-tert-butylphenol, erythorbic acid, gum guaiac, propyl gallate, thiodipropionic acid, dilauryl thiodipropionate, tert-butylhydroquinone, tocopherol, and pharmaceutically acceptable salt and ester thereof, and combinations thereof.
21 . The method of claim 11 , wherein the subject has a disorder selected from the group consisting of alopecia areata, alopecia totalis, alopecia universalis, vitiligo, graft versus host disease, telogen effluvium, tinea capitis (dermatophytosis), hypotrichosis, hereditary hypotrichosis simplex, frontal fibrosing alopecia, cicatricial alopecia, lichen planopilaris, ring alopecia, and chemotherapy induced alopecia.